Lilly And AC Immune Partner On A Small Molecule With Potential In Alzheimer's Combinations

Eli Lilly signed a licensing deal to develop a tau aggregation inhibitor small molecule for Alzheimer's disease – a drug that works differently from existing antibodies and could offer potential in combination regimens. AC Immune CEO Andrea Pfeifer talked to Scrip about the deal.

Puzzle

Eli Lilly & Co. has partnered with the Swiss neurodegenerative disease specialist AC Immune SA to develop tau-aggregation inhibitors, which are small molecules that could offer big potential as combination therapies with amyloid-beta antibodies. Combination therapy is where the industry increasingly is interested in going in Alzheimer's disease as clinical trial failures for various monotherapies pile up.

"It's the first small molecule in the world which directly interacts with pathological tau," AC Immune CEO Andrea Pfeifer said...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category